1M6MYTD1R5LMAX
Wczytywanie kursów wyceny...
Prognoza
| Kupuj |
2 |
| Trzymaj |
0 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
Phio Pharmaceuticals secures patent grants in US, Canada and Japan
Phio Pharmaceuticals reports three patent allowances and one grant decision to protect its INTASYL active agents in the US, Canada and Japan. The portfolio now comprises 54 granted patents covering chemistry, gene targets, immuno-oncology agents and indications. The company views the expanded protection as supporting strategic partnerships and commercialization, but with a market capitalization of USD 11.97 million and a negative free cash flow of USD 10.72 million it remains in the capital-intensive clinical development phase. The stock trades below InvestingPro’s fair-value estimate. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | -876,21 | 99,90% |
| Zysk netto | -3,63 mln | 97,30% |
| EBITDA | -3,74 mln | 103,50% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 10,4 mln € |
Liczba akcji | 11,62 mln |
Maksimum/minimum z 52 tygodni | 3,68 € - 0,71 € |
| Dywidendy | Nie |
Beta | 0,80 |
C/Z (PE Ratio) | -0,76 |
PEG (PEG Ratio) | -0,01 |
C/WK (PB Ratio) | 0,94 |
C/S (PS Ratio) | 0,00 |
Profil spółki
| Nazwa | Phio Pharmaceuticals Corp |
| CEO | Robert L. Bitterman |
| Pracownicy | 6 |
